slc-391
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 31, 2019 (NCT03990454)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tyrosine-protein kinase receptor UFOINHIBITOR
AXL inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Nc1ncc(-c2cnn(C3CCNCC3)c2)cc1-c1nnc(CC2CC2)o1- Mol. weight
- 365.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095196 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05860296 | Phase 1/Phase 2 (Phase 2) | May 31, 2023 | Merck, SignalChem Lifesciences Corporation |
| NCT05278845 | Phase 1 | Feb 12, 2022 | SignalChem Lifesciences Corporation, Syneos Health |
| NCT03990454 | Phase 1 | Jul 31, 2019 | SignalChem Lifesciences Corporation |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SignalChem Lifesciences Corporation | For profit | 3 | 3 | 2 | 2019 |
| Merck | For profit | 1 | 0 | 1 | 2023 |
| Syneos Health | For profit | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1